Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  GeNeuro    GNRO   CH0308403085

GENEURO (GNRO)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 10/23 09:29:05 am
4.07 EUR   -2.16%
09/20GENEURO : Half-year results
CO
09/17GENEURO SA : half-yearly earnings release
06/30GENEURO : Half-year report
CO
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
10/17/2018 10/18/2018 10/19/2018 10/22/2018 10/23/2018 Date
4.25(c) 4.24(c) 4.15(c) 4.16(c) 4.07 Last
5 671 589 1 255 106 791 Volume
0.00% -0.24% -2.12% +0.24% -2.16% Change
More quotes
Financials (EUR)
Sales 2018 8,00 M
EBIT 2018 -10,3 M
Net income 2018 -9,80 M
Finance 2018 13,2 M
Yield 2018 -
Sales 2019 7,50 M
EBIT 2019 -6,80 M
Net income 2019 -7,80 M
Finance 2019 4,80 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 5,95x
EV / Sales2019 7,46x
Capitalization 60,7 M
More Financials
Company
GeNeuro SA engages in the research and development of pharmaceutical products.It offers GNbAC1, a therapeutic antibody that targets MSRV-Env.It also offers a drug for multiple sclerosis.The company was founded by Herve Perron, Christophe Merieux, and Jesus Martin-Garcia in 2006 and is headquartered... 
More about the company
Surperformance© ratings of GeNeuro
Trading Rating : Investor Rating :
More Ratings
Latest news on GENEURO
10/11GENEURO : to Present 12 Month Data on Anti-neurodegeneration Effects of GNbAC1 f..
AQ
09/20GENEURO : Half-year results
CO
09/17GENEURO SA : half-yearly earnings release
06/30GENEURO : Half-year report
CO
05/24GENEURO : Press Release
CO
05/24GENEURO : Proxy Statments
CO
05/09GENEURO : 1st quarter earnings
CO
03/29GENEURO SA : annual earnings release
03/29GENEURO : and Servier announce successful 12-month results in neuroprotection fo..
AQ
02/24GENEURO : Receives Orphan Drug Designation from the US FDA for GNbAC1 in Chronic..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
10/21Roche takes on Loxo, Bayer in gene-defined cancer class
RE
10/19FDA Approves Asthma Indication for Regeneron and Sanofi's Dupixent
DJ
10/16Sanofi's Dupixent Shows Positive Headline Results in Two Phase 3 Studies
DJ
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
10/17Geneuro moves beyond @servier with pHERV-K antibodies for ALS, inking deal wi.. 
10/17GeNeuro $GNRO Confirms Potential of Novel pHERV-K Antibodies for ALS in Colla..
1
10/15Geneuro #ECTRIMS2018 presentation (CHANGE-MS 48wks GnbAC1 in RR-MS)
2
09/26$GNRO GENEURO: GNbAC1 delivers positive safety data in T1D but limited effic.. 
09/26Positive 6mo data... on safety, 0 interpretable date on efficacy = (either o..
1
More tweets
Qtime:7
News from SeekingAlpha
07/26GeNeuro reports Q2 results 
05/09GeNeuro reports Q1 results 
02/12GENEURO SA ORD reports Q4 results 
2017GENEURO SA ORD reports Q3 results 
2017GeNeuro (GNRRF) Presents Review Of Phase llb Week-24 Results - Slideshow 
Chart GENEURO
Duration : Period :
GeNeuro Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENEURO
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 9,43 €
Spread / Average Target 127%
EPS Revisions
Managers
NameTitle
Jesús Martin-Garcia Chairman & Chief Executive Officer
François Curtin Chief Operating Officer
Miguel Payro Chief Financial Officer
Hervé Perron Chief Scientific Officer
Robert Glanzman Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
GENEURO-27.15%73
CELLTRION, INC.--.--%28 844
IQVIA HOLDINGS INC29.16%26 016
LONZA GROUP23.59%24 556
INCYTE CORPORATION-31.18%13 698
SEATTLE GENETICS, INC.34.21%11 706